Scinai Immunotherapeutics (NASDAQ:SCNI) vs. Adaptimmune Therapeutics (NASDAQ:ADAP) Head to Head Survey

Adaptimmune Therapeutics (NASDAQ:ADAP) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Adaptimmune Therapeutics and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adaptimmune Therapeutics	-25.43%	-74.15%	-15.09%
Scinai Immunotherapeutics	N/A	N/A	-30.48%

Institutional and Insider Ownership

31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Adaptimmune Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Adaptimmune Therapeutics and Scinai Immunotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptimmune Therapeutics	0	0	4	0	3.00
Scinai Immunotherapeutics	0	0	0	0	0.00

Adaptimmune Therapeutics presently has a consensus target price of $2.79, suggesting a potential upside of 364.58%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Adaptimmune Therapeutics is more favorable than Scinai Immunotherapeutics.

Valuation & Earnings

This table compares Adaptimmune Therapeutics and Scinai Immunotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptimmune Therapeutics	$175.04 million	0.88	-$113.87 million	($0.22)	-2.73
Scinai Immunotherapeutics	$452,000.00	6.36	-$6.50 million	($239.17)	-0.01

Scinai Immunotherapeutics has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Scinai Immunotherapeutics beats Adaptimmune Therapeutics on 8 of the 14 factors compared between the two stocks.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.